Updates in Small Interfering RNA for the Treatment of Dyslipidemias

Creative Commons License

Carugo S., Sirtori C., Gelpi G., Corsini A., Tokgozoglu L., Ruscica M.

Current Atherosclerosis Reports, vol.25, no.11, pp.805-817, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 25 Issue: 11
  • Publication Date: 2023
  • Doi Number: 10.1007/s11883-023-01156-5
  • Journal Name: Current Atherosclerosis Reports
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.805-817
  • Keywords: ARO-ANG3, ARO-APOC3, Inclisiran, Lipid-lowering therapy, Olpasiran
  • Hacettepe University Affiliated: Yes


Purpose of Review: Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of death worldwide. Despite excellent pharmacological approaches, clinical registries consistently show that many people with dyslipidemia do not achieve optimal management, and many of them are treated with low-intensity lipid-lowering therapies. Beyond the well-known association between low-density lipoprotein cholesterol (LDL-C) and cardiovascular prevention, the atherogenicity of lipoprotein(a) and the impact of triglyceride (TG)-rich lipoproteins cannot be overlooked. Within this landscape, the use of RNA-based therapies can help the treatment of difficult to target lipid disorders. Recent Findings: The safety and efficacy of LDL-C lowering with the siRNA inclisiran has been documented in the open-label ORION-3 trial, with a follow-up of 4 years. While the outcome trial is pending, a pooled analysis of ORION-9, ORION-10, and ORION-11 has shown the potential of inclisiran to reduce composite major adverse cardiovascular events. Concerning lipoprotein(a), data of OCEAN(a)-DOSE trial with olpasiran show a dose-dependent drop in lipoprotein(a) levels with an optimal pharmacodynamic profile when administered every 12 weeks. Concerning TG lowering, although ARO-APOC3 and ARO-ANG3 are effective to lower apolipoprotein(apo)C-III and angiopoietin-like 3 (ANGPTL3) levels, these drugs are still in their infancy. Summary: In the era moving toward a personalized risk management, the use of siRNA represents a blossoming armamentarium to tackle dyslipidaemias for ASCVD risk reduction.